Aurobindo Pharmaceuticals has settled claims for $2 million to resolve economic loss allegations stemming from contaminated irbesartan products sold between January 1, 2016 and the present. The settlement addresses a widespread problem affecting multiple blood pressure drug manufacturers: nitrosamine contamination, specifically NDMA, NDEA, and NMBA impurities that the FDA has classified as probable human carcinogens. Consumers who purchased irbesartan manufactured using Aurobindo’s IC Route of Synthesis—the active pharmaceutical ingredient source—may be eligible to file claims for what they overpaid when buying contaminated medications.
This settlement represents one piece of a much larger multidistrict litigation (MDL) addressing contaminated sartan medications. The broader litigation has generated $15.26 million in total settlements across Aurobindo, Hetero, and other manufacturers. The Aurobindo settlement specifically addresses economic harm—the money consumers lost by purchasing drugs that contained dangerous impurities—rather than personal injury claims, which are being litigated separately and may result in additional compensation for people who suffered actual medical harm.
Table of Contents
- What Is NDMA Contamination and Why Does It Matter in Blood Pressure Medications?
- Details of the Aurobindo Settlement: What’s Covered and What Isn’t
- How the Aurobindo Settlement Fits Into the Broader Sartan Drug MDL
- Who Is Eligible to Claim and How to File
- Important Limitations: What This Settlement Does and Doesn’t Provide
- Timeline and Court Proceedings: Final Approval and Beyond
- What to Do If You Purchased Aurobindo-Sourced Irbesartan
- Frequently Asked Questions
What Is NDMA Contamination and Why Does It Matter in Blood Pressure Medications?
NDMA (N-nitrosodimethylamine) is a toxic compound that can form during the manufacturing process of certain active pharmaceutical ingredients, particularly those produced using specific synthesis routes. When NDMA and related nitrosamines contaminate blood pressure medications, they create a double harm: patients believe they are taking safe medication to manage a serious condition, but they are instead ingesting substances the FDA considers probable carcinogens. The contamination was not the fault of the pharmacies or prescribing doctors—it originated in the manufacturing process at the API level, making it a systemic problem that affected multiple companies sourcing ingredients from the same routes.
The specific risk from NDMA exposure is significant enough that in 2018, the FDA began investigating and ultimately recalled numerous batches of valsartan, losartan, and irbesartan medications. The agency determined that certain manufacturing processes—particularly those used by Aurobindo and other API suppliers—created conditions where nitrosamines could form as byproducts. Unlike bacterial contamination that might be caught by routine testing, nitrosamine impurities can be difficult to detect and eliminate, meaning contaminated batches may have been distributed for months or years before problems were identified.
Details of the Aurobindo Settlement: What’s Covered and What Isn’t
The $2 million Aurobindo settlement covers “economic loss” claims—essentially, refunds or compensation for consumers who overpaid for contaminated medications. If you purchased irbesartan made with Aurobindo’s IC Route of Synthesis ingredients, the settlement permits you to claim reimbursement for what you paid out of pocket, including copays and full cash purchases. The settlement does not, however, cover personal injury claims or medical monitoring expenses. Those categories are being pursued separately through the litigation, meaning if you suffered an illness related to NDMA exposure, your claim for medical treatment or ongoing monitoring would go through a different legal track.
This split coverage structure is important to understand because it affects both the amount of compensation you might receive and the timeline for receiving it. Economic loss claims tend to be lower per person but simpler to process—the company only needs to verify that you purchased the drug during the class period. Personal injury claims require medical evidence, expert testimony, and individual assessments of causation, which take significantly longer to resolve but can result in far larger awards for people who can prove actual harm. The economic settlement is resolved through this MDL; injured parties may pursue separate litigation or await resolution of the personal injury track within the same court proceedings.
How the Aurobindo Settlement Fits Into the Broader Sartan Drug MDL
The Aurobindo settlement is part of a coordinated effort to resolve contamination claims against multiple manufacturers simultaneously. The broader MDL has generated $15.26 million in total settlements across companies including Aurobindo and Hetero, among others. This structure allows the court to handle thousands of claims efficiently rather than forcing individual consumers to file separate lawsuits against each company. The MDL is being managed by the U.S. District Court for the District of New Jersey, which has become the central forum for sartan contamination litigation nationwide.
The broader context matters because it shows regulators and courts taking the contamination seriously enough to pursue multiple defendants. Some manufacturers settled quickly; others required more litigation pressure. By consolidating claims, the MDL also ensures that consumers get consistent treatment and information regardless of which company sold them the contaminated drug. If Aurobindo had settled for $2 million while other manufacturers faced identical contamination claims with minimal consequences, it would signal that the problem wasn’t serious. Instead, the coordinated settlements across the industry suggest that manufacturers recognize both legal liability and reputational risk.
Who Is Eligible to Claim and How to File
To be eligible for the Aurobindo settlement, you must have purchased irbesartan during the class period (January 1, 2016 through present) that was manufactured using Aurobindo’s IC Route of Synthesis. This is a specific requirement because Aurobindo supplied active pharmaceutical ingredients to other manufacturers, but not all irbesartan sold during this time period came from Aurobindo’s synthesis route. Your pharmacy records, prescription bottles, or insurance documentation should indicate which manufacturer supplied the API; if you’re unsure, the settlement administrator’s website will have tools to help you identify whether your purchase qualifies. The claim deadline is June 2, 2026—a hard stop for submitting claims.
Anyone who misses this date loses the right to participate in the settlement. Claims are typically filed online through the settlement administrator’s portal, though paper claims may be available. You will need documentation of your purchase (pharmacy receipt, prescription record, or insurance explanation of benefits showing copay). The process is straightforward for economic loss claims because you’re not claiming personal injury; the settlement only requires proof that you purchased the contaminated product and what you paid. If you can’t locate original receipts, pharmacy records or insurance records can substitute, so don’t assume you’re ineligible if you’ve discarded paperwork.
Important Limitations: What This Settlement Does and Doesn’t Provide
One critical limitation: this settlement covers only economic loss, meaning you recover money for overpayment, not compensation for any medical condition you may have developed. If you took contaminated irbesartan and later developed cancer or other serious illness, this $2 million settlement will not compensate you for medical expenses or pain and suffering. Your recourse for personal injury claims exists but follows a separate track in the litigation. This means you may eventually receive additional compensation through personal injury litigation, but it is not automatic and requires different proof. Another limitation is that the $2 million must be divided among all eligible claimants.
If there are 50,000 valid claims, each person receives far less than if there are 10,000 claims. The settlement fund is fixed; it does not increase if more people file claims. This is different from some settlements where each claimant receives a guaranteed amount. Here, your actual recovery depends on the claims-filing rate and the total amount you paid for the contaminated medication. Someone who took one 30-day supply may receive a nominal check, while someone who purchased multiple prescriptions over years might receive more substantial compensation.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Timeline and Court Proceedings: Final Approval and Beyond
The Final Approval Hearing is scheduled for June 30, 2026 at 10:00 AM in Courtroom 3D of the U.S. District Court for the District of New Jersey. This hearing is where the judge will formally approve the settlement, assuming no major objections or problems emerge. The hearing is public, though most claimants do not attend.
If you want to object to the settlement terms or the attorneys’ fee request (a portion of the settlement typically goes to the plaintiffs’ lawyers), you must file a formal objection before the hearing date and can attend in person to voice your objection. After final approval, the settlement administrator begins processing claims. Expect a wait of several months to a year before receiving your check, as the administrator must verify each claim, determine eligibility, and coordinate distribution of the settlement fund. The June 2, 2026 claim deadline comes before the final approval hearing, which means you must file before the judge even formally approves the deal. This timing is standard in MDL settlements; it ensures the court has a clear picture of how many claims it will need to administer before the hearing.
What to Do If You Purchased Aurobindo-Sourced Irbesartan
Locate any pharmacy records or insurance documentation showing irbesartan purchases between January 1, 2016 and the present. Your pharmacy may retain records for seven years or longer, so contact them directly if you’ve lost your receipts. Many insurance companies provide online access to prescription history, which will show the drug name, manufacturer, and what you paid out of pocket. Alternatively, if you used an FSA or HSA to pay, those accounts maintain records of pharmacy purchases.
Once you’ve confirmed your purchase, visit the settlement administrator’s website to file your claim before the June 2, 2026 deadline. Have your prescription records and proof of payment ready. Do not wait until late May to file; settlement websites often experience high traffic near the deadline, and technical issues could prevent you from submitting on time. If your claim is denied for any reason, you will receive an explanation; many denials can be remedied by providing additional documentation of your purchase or clarification that your irbesartan came from Aurobindo’s manufacturing route.
Frequently Asked Questions
Does the Aurobindo settlement cover personal injury claims?
No. This settlement covers only economic loss (money you paid for contaminated medication). Personal injury and medical monitoring claims are litigated separately and may result in additional compensation.
What is the deadline to file a claim?
June 2, 2026. This is a hard deadline; claims submitted after this date will not be accepted.
How much will I receive from my claim?
The amount depends on how many valid claims are filed and how much you paid out of pocket for irbesartan during the class period. The $2 million settlement fund is divided among all eligible claimants.
What documentation do I need to file a claim?
Proof of purchase (pharmacy receipt, prescription bottle, insurance explanation of benefits, or pharmacy record) showing you purchased irbesartan manufactured with Aurobindo’s IC Route of Synthesis between January 1, 2016 and present.
Is the final approval hearing open to the public?
Yes. The hearing is June 30, 2026 at 10:00 AM in Courtroom 3D of the U.S. District Court for the District of New Jersey. You can attend if you wish to object or simply observe.
Can I file a claim if I don’t have my original pharmacy receipt?
Yes. Pharmacy records, insurance documentation, or FSA/HSA records showing the purchase can substitute for original receipts.
You Might Also Like
- NextEra Nuclear Plant Wage Class Action Settlement Resolves Claims Worker Pay Was Suppressed
- Grubhub Driver Settlement Resolves Claims California Delivery Workers Were Misclassified
- GlaxoSmithKline Flu Shot Marketing Settlement Resolves Claims Over Vaccine Advertising